Which has higher earnings and valuation, VSN or COIL?

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verseon N/A N/A N/A -£14.30 N/A Roquefort Therapeutics N/A N/A -£1.52M -£21.90 N/A

Which has stronger earnings and valuation, COIL or MPH?

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roquefort Therapeutics N/A N/A -£1.52M -£21.90 N/A Mereo BioPharma Group plc (MPH.L) N/A N/A N/A -£128.00 N/A

Roquefort Therapeutics (COIL) Competitors

GBX 10 0.00 (0.00%)

As of 12:02 PM Eastern

Compare

COIL vs. CIR, SCLP, TILS, VSN, and MPH

Should you buy Roquefort Therapeutics stock or one of its competitors? MarketBeat compares Roquefort Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Roquefort Therapeutics include Circassia Group (CIR), Scancell (SCLP), Tiziana Life Sciences (TILS), Verseon (VSN), and Mereo BioPharma Group plc (MPH.L) (MPH). These companies are all part of the "biotechnology" industry.

How does Roquefort Therapeutics compare to Circassia Group?

Circassia Group (LON:CIR) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Circassia Group has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Circassia Group's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circassia Group	N/A	N/A	N/A
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company	Overall Sentiment
Circassia Group	Neutral
Roquefort Therapeutics	Neutral

2.1% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Circassia Group has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A

Summary

Circassia Group beats Roquefort Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Scancell?

Scancell (LON:SCLP) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Scancell has a beta of 0.736, meaning that its share price is 26% less volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market.

Roquefort Therapeutics has lower revenue, but higher earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	29.47	-£6.75M	-£0.55	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A

Scancell has a net margin of -116.98% compared to Roquefort Therapeutics' net margin of -57,057.07%. Scancell's return on equity of 90.29% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%

In the previous week, Scancell had 1 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Roquefort Therapeutics. Scancell's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company	Overall Sentiment
Scancell	Neutral
Roquefort Therapeutics	Neutral

1.5% of Scancell shares are owned by institutional investors. Comparatively, 2.1% of Roquefort Therapeutics shares are owned by institutional investors. 15.5% of Scancell shares are owned by insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Scancell beats Roquefort Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Tiziana Life Sciences has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Tiziana Life Sciences' return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%

2.1% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tiziana Life Sciences' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company	Overall Sentiment
Tiziana Life Sciences	Neutral
Roquefort Therapeutics	Neutral

Tiziana Life Sciences has higher earnings, but lower revenue than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A

Summary

Tiziana Life Sciences and Roquefort Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Verseon?

Verseon (LON:VSN) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

2.1% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verseon	N/A	N/A	N/A	-£14.30	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A

Verseon has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Verseon's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verseon	N/A	N/A	N/A
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%

In the previous week, Verseon's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company	Overall Sentiment
Verseon	Neutral
Roquefort Therapeutics	Neutral

Summary

Verseon beats Roquefort Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Roquefort Therapeutics (LON:COIL) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Mereo BioPharma Group plc (MPH.L)'saverage media sentiment score.

Company	Overall Sentiment
Roquefort Therapeutics	Neutral
Mereo BioPharma Group plc (MPH.L)	Neutral

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A

2.1% of Roquefort Therapeutics shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Mereo BioPharma Group plc (MPH.L) beats Roquefort Therapeutics on 4 of the 7 factors compared between the two stocks.

Get Roquefort Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COIL vs. The Competition

Export

Metric	Roquefort Therapeutics	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£42.68M	£515.16M	£6.81B	£2.79B
Dividend Yield	N/A	3.90%	2.67%	6.16%
P/E Ratio	-0.46	3.15	27.00	368.25
Price / Sales	N/A	6,249.84	517.32	84,392.87
Price / Cash	1.49	13.13	26.68	27.89
Price / Book	2.62	87.68	10.67	7.59
Net Income	-£1.52M	-£96.07M	£3.60B	£5.89B
7 Day Performance	N/A	-0.59%	-0.37%	0.05%
1 Month Performance	-3.57%	1.23%	1.80%	-0.66%
1 Year Performance	-41.18%	60.49%	25.50%	62.48%

Roquefort Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COIL Roquefort Therapeutics	N/A	GBX 10 flat	N/A	-28.6%	£42.68M	N/A	N/A	9
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
SCLP Scancell	N/A	GBX 13.40 +1.5%	N/A	+32.0%	£139.06M	£4.71M	N/A	51	Gap Up
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:COIL) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roquefort Therapeutics (COIL) Competitors

COIL vs. CIR, SCLP, TILS, VSN, and MPH

How does Roquefort Therapeutics compare to Circassia Group?

Summary

How does Roquefort Therapeutics compare to Scancell?

Summary

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Summary

How does Roquefort Therapeutics compare to Verseon?

Summary

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COIL vs. The Competition

Roquefort Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roquefort Therapeutics (COIL) Competitors

COIL vs. CIR, SCLP, TILS, VSN, and MPH

How does Roquefort Therapeutics compare to Circassia Group?

Is CIR or COIL more profitable?

Does the media favor CIR or COIL?

Do insiders & institutionals hold more shares of CIR or COIL?

Which has better earnings and valuation, CIR or COIL?

Summary

How does Roquefort Therapeutics compare to Scancell?

Which has more volatility and risk, SCLP or COIL?

Which has higher valuation and earnings, SCLP or COIL?

Is SCLP or COIL more profitable?

Does the media prefer SCLP or COIL?

Do institutionals and insiders have more ownership in SCLP or COIL?

Summary

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Is TILS or COIL more profitable?

Do insiders & institutionals believe in TILS or COIL?

Does the media favor TILS or COIL?

Which has better earnings & valuation, TILS or COIL?

Summary

How does Roquefort Therapeutics compare to Verseon?

Do institutionals and insiders have more ownership in VSN or COIL?

Which has higher earnings and valuation, VSN or COIL?

Is VSN or COIL more profitable?

Does the media favor VSN or COIL?

Summary

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Is COIL or MPH more profitable?

Does the media favor COIL or MPH?

Which has stronger earnings and valuation, COIL or MPH?

Do institutionals and insiders hold more shares of COIL or MPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COIL vs. The Competition

Roquefort Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools